Final report of radiation therapy oncology group protocol 9003: Provocative, but limited conclusions from exploratory analyses

International Journal of Radiation Oncology Biology Physics

Volumn 92, Issue 4, 2015, Pages 715-717

  Rosenthal, David I ^a   Fuller, Clifton D ^a   Peters, Lester J ^b   Thames, Howard D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CONTROL; CHEMORADIOTHERAPY; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; NOTE; ONCOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; TREATMENT PLANNING; CARCINOMA, SQUAMOUS CELL; DOSE FRACTIONATION; HEAD AND NECK NEOPLASMS; HUMANS;

CARCINOMA, SQUAMOUS CELL; DOSE FRACTIONATION; HEAD AND NECK NEOPLASMS; HUMANS;

EID: 84931413748     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2015.02.051     Document Type: Editorial

References (19)

1. J.J. Beitler, Q. Zhang, and K.K. Fu Final results of local-regional control and late toxicity of RTOG 9003: A randomized trial of altered fractionation radiation for locally advanced head and neck cancer Int J Radiat Oncol Biol Phys 89 2014 13 20
2. V.A. Marcial, T.F. Pajak, and C. Chang Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary-report) by the Radiation Therapy Oncology Group (RTOG) Int J Radiat Oncol Biol Phys 13 1987 41 47
3. S.M. Bentzen, and H.D. Thames Dose-response relationships for late radiation effects in the head and neck: Regarding the analysis of the RTOG 8313 trial, Fu et al. IJROBP 32:577-588; 1995 Int J Radiat Oncol Biol Phys 34 1996 523 524
4. J.D. Cox, T.F. Pajak, and V.A. Marcial Interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts - results from Radiation-Therapy Oncology Group protocol 8313 Int J Radiat Oncol Biol Phys 20 1991 1191 1195
5. K.A. Hutcheson, J.S. Lewin, and D.A. Barringer Late dysphagia after radiotherapy-based treatment of head and neck cancer Cancer 118 2012 5793 5799
6. J.T. Parsons, W.M. Mendenhall, and S.P. Stringer Twice-a-day radiotherapy for squamous-cell carcinoma of the head and neck - The University of Florida experience Head Neck 15 1993 87 96
7. K.K. Ang, L.J. Peters, and R.S. Weber Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx Int J Radiat Oncol Biol Phys 19 1990 1339 1345
8. C.C. Wang Local control of oropharyngeal carcinoma after two accelerated hyperfractionation radiation therapy schemes Int J Radiat Oncol Biol Phys 14 1988 1143 1146
9. C.C. Wang, J. Efird, and B. Nakfoor Local control of t3 carcinomas after accelerated fractionation: A look at the "gap" Int J Radiat Oncol Biol Phys 35 1996 439 441
10. J.C. Horiot, R. Lefur, and T. Nguyen Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma - final analysis of a randomized trial of the EORTC cooperative group of radiotherapy Radiother Oncol 25 1992 231 241
11. J. Bourhis, C. Sire, and P. Graff Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): An open-label phase 3 randomised trial Lancet Oncol 13 2012 145 153
12. J. Overgaard, H.S. Hansen, and L. Specht Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial Lancet 362 2003 933 940
13. J. Overgaard, B.K. Mohanti, and N. Begum Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): A randomised, multicentre trial Lancet Oncol 11 2010 553 560
14. S. Ghoshal, J.S. Goda, and I. Mallick Concomitant boost radiotherapy compared with conventional radiotherapy in squamous cell carcinoma of the head and neck - A phase III trial from a single institution in India Clin Oncol 20 2008 212 220
15. J. Bourhis, J. Overgaard, and H. Audry Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis Lancet 368 2006 843 854
16. H.E. Newlin, R.J. Amdur, and C.E. Riggs Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer Cancer 116 2010 4533 4540
17. K.K. Ang, Q. Zhang, and D.I. Rosenthal Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522 J Clin Oncol 32 2014 2940 2950
18. K. Ang A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (hnc): Impact of radiation and cisplatin intensity on outcome [Abstract] J Clin Oncol 28 suppl.15 2010 5507
19. D.M. Brizel, M.E. Albers, and S.R. Fisher Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer N Engl J Med 338 1998 1798 1804